Linking angiogenesis to bone destruction in arthritis

Arthritis and Rheumatism

Volumn 52, Issue 5, 2005, Pages 1346-1348

  Pap, Thomas ^a   Distler, Oliver ^b  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; ANGIOPOIETIN 1; ANGIOSTATIN; BEVACIZUMAB; COLLAGEN; FOCAL ADHESION KINASE; INTERSTITIAL COLLAGENASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OSTEOCLAST DIFFERENTIATION FACTOR; PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA; TYROSINE KINASE RECEPTOR; TYROSINE KINASE RECEPTOR 2; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ALLELE; ANGIOGENESIS; ARTHRITIS; BONE DESTRUCTION; CARTILAGE DEGENERATION; CELL MIGRATION; CELL PROLIFERATION; CHEMOTAXIS; CHRONIC ARTHRITIS; COLLAGEN INDUCED ARTHRITIS; COLORECTAL CANCER; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG APPROVAL; EDITORIAL; ENDOTHELIUM CELL; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERPLASIA; INFLAMMATION; INFLAMMATORY CELL; KNOCKOUT MOUSE; OSTEOCLAST; OSTEOLYSIS; PATHOGENESIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIAL HYPERPLASIA; SYNOVITIS; SYNOVIUM; SYSTEMATIC REVIEW;

ARTHRITIS, RHEUMATOID; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 18644369141     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21015     Document Type: Editorial

References (23)

1. Distler JH, Wenger RH, Gassmann M, Kurowska M, Hirth A, Gay S, et al. Physiologic responses to hypoxia and implications for hypoxia-inducible factors in the pathogenesis of rheumatoid arthritis [review]. Arthritis Rheum 2004;50:10-23.
2. Sivakumar B, Harry LE, Paleolog EM. Modulating angiogenesis: more vs less. JAMA 2004;292:972-7.
3. Distler JH, Hirth A, Kurowska-Stolarska M, Gay RE, Gay S, Distler O. Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q J Nucl Med 2003;47:149-61.
4. Hirohata S, Sakakibara J. Angioneogenesis as a possible elusive triggering factor in rheumatoid arthritis [letter]. Lancet 1999;353:1331.
5. Clavel G, Bessis N, Boissier MC. Recent data on the role for angiogenesis in rheumatoid arthritis. Joint Bone Spine 2003;70:321-6.
6. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
7. Chen Y, Donnelly E, Kobayashi H, DeBusk LM, Lin PC. Gene therapy targeting the Tie2 function ameliorates collagen-induced arthritis and protects against bone destruction. Arthritis Rheum 2005;52:1585-94.
8. DeBusk LM, Chen Y, Nishishita T, Chen J, Thomas JW, Lin PC. Tie2 receptor tyrosine kinase, a major mediator of tumor necrosis factor α-induced angiogenesis in rheumatoid arthritis. Arthritis Rheum 2003;48:2461-71.
9. Gravallese EM, Pettit AR, Lee R, Madore R, Manning C, Tsay A, et al. Angiopoietin-1 is expressed in the synovium of patients with rheumatoid arthritis and is induced by tumour necrosis factor α. Ann Rheum Dis 2003;62:100-7.
10. Scott BB, Zaratin PF, Colombo A, Hansbury MJ, Winkler JD, Jackson JR. Constitutive expression of angiopoietin-1 and -2 and modulation of their expression by inflammatory cytokines in rheumatoid arthritis synovial fibroblasts. J Rheumatol 2002;29:230-9.
11. Shahrara S, Volin MV, Connors MA, Haines GK, Koch AE. Differential expression of the angiogenic Tie receptor family in arthritic and normal synovial tissue. Arthritis Res 2002;4:201-8.
12. Nagashima M, Tanaka H, Takahashi H, Tachihara A, Tanaka K, Ishiwata T, et al. Study of the mechanism involved in angiogenesis and synovial cell proliferation in human synovial tissues of patients with rheumatoid arthritis using SCID mice. Lab Invest 2002;82:981-8.
13. De Bandt M, Grossin M, Weber AJ, Chopin M, Elbim C, Pla M, et al. Suppression of arthritis and protection from bone destruction by treatment with TNP-470/AGM-1470 in a transgenic mouse model of rheumatoid arthritis. Arthritis Rheum 2000;43:2056-63.
14. Lu J, Kasama T, Kobayashi K, Yoda Y, Shiozawa F, Hanyuda M, et al. Vascular endothelial growth factor expression and regulation of murine collagen-induced arthritis. J Immunol 2000;164:5922-7.
15. Sone H, Kawakami Y, Sakauchi M, Nakamura Y, Takahashi A, Shimano H, et al. Neutralization of vascular endothelial growth factor prevents collagen-induced arthritis and ameliorates established disease in mice. Biochem Biophys Res Commun 2001;281:562-8.
16. Miotla J, Maciewicz R, Kendrew J, Feldmann M, Paleolog E. Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis. Lab Invest 2000;80:1195-205.
17. Nakagawa M, Kaneda T, Arakawa T, Morita S, Sato T, Yomada T, et al. Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts. FEBS Lett 2000;473:161-4.
18. Matsumoto Y, Tanaka K, Hirata G, Hanada M, Matsuda S, Shuto T, et al. Possible involvement of the vascular endothelial growth factor-Flt-1-focal adhesion kinase pathway in chemotaxis and the cell proliferation of osteoclast precursor cells in arthritic joints. J Immunol 2002;168:5824-31.
19. Kim JM, Ho SH, Park EJ, Hahn W, Cho H, Jeong JG, et al. Angiostatin gene transfer as an effective treatment strategy in murine collagen-induced arthritis. Arthritis Rheum 2002;46:793-801.
20. Peyruchaud O, Serre CM, NicAmhlaoibh R, Fournier P, Clezardin P. Angiostatin inhibits bone metastasis formation in nude mice through a direct anti-osteoclastic activity. J Biol Chem 2003;278:45826-32.
21. Collin-Osdoby P, Rothe L, Anderson F, Nelson M, Maloney W, Osdoby P. Receptor activator of NF-κB and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem 2001;276:20659-72.
22. Min JK, Kim YM, Kim EC, Gho YS, Kang IJ, Lee SY, et al. Vascular endothelial growth factor up-regulates expression of receptor activator of NF-κB (RANK) in endothelial cells: concomitant increase of angiogenic responses to RANK ligand. J Biol Chem 2003;278:39548-57.
23. Henriksen K, Karsdal M, Delaisse JM, Engsig MT. RANKL and vascular endothelial growth factor (VEGF) induce osteoclast chemotaxis through an ERK1/2-dependent mechanism. J Biol Chem 2003;278:48745-53.